GLP-1 receptor agonists, such as semaglutide, have revolutionized obesity management by effectively reducing body weight predominantly through appetite suppression and improved glycemic control. However, a significant limitation of this class of drugs is their associated loss of lean mass—up to 40% of total weight lost during treatment can be from muscle tissue, which may compromise patients’ metabolic health and physical function. The introduction of bimagrumab, which antagonizes the activin type II receptors to promote muscle growth and inhibit muscle wasting, offers a compelling solution to this challenge.

The BELIEVE study meticulously evaluated the efficacy and safety of semaglutide alone, bimagrumab alone, and their combination, over a sustained treatment period of 72 weeks. Participants were randomly assigned to one of nine groups, encompassing two dosages of bimagrumab (10 mg/kg and 30 mg/kg administered every 12 weeks) combined with two dosages of semaglutide (1.0 mg and 2.4 mg administered weekly), or the individual administration of each agent. This robust design enabled a comprehensive assessment of dose-dependent responses and the additive impact on body composition.

Remarkably, individuals treated solely with bimagrumab experienced an average weight loss of 10.8%, which was exclusively attributed to fat mass reduction, paralleled by an unexpected 2.5% increase in lean mass. Conversely, participants receiving semaglutide alone shed an average of 15.7% of their body weight, with 71.8% of this loss derived from fat mass, indicating that lean mass depletion was still a concern. Most notably, the cohort administered the combination therapy demonstrated an impressive average weight loss of 22.1%, with a predominant 92.8% of weight loss from fat mass, while lean mass was substantially preserved.

These findings underscore the potential of the combination therapy to circumvent the deleterious loss of skeletal muscle commonly seen with GLP-1 receptor agonists, thereby optimizing metabolic outcomes and physical functionality among patients with obesity. Dr. Heymsfield emphasized, “Our data reveal that bimagrumab and semaglutide operate through distinct yet complementary biological pathways. When combined, they maximize fat loss and for the first time in large clinical trials, demonstrate significant lean mass retention alongside profound weight reduction.”

Beyond weight loss metrics, the study elucidated systemic metabolic improvements associated with the treatment regimens. Participants showed up to an 83% reduction in high-sensitivity C-reactive protein (hsCRP), a robust biomarker for systemic inflammation and cardiovascular risk. Furthermore, there was a substantial elevation in adiponectin levels, a hormone intimately involved in enhancing insulin sensitivity, fostering lipid metabolism, and exerting anti-inflammatory effects, which collectively contribute to cardiometabolic health.

In a clinically relevant subgroup exhibiting prediabetic markers at baseline, the combination therapy achieved a 100% reversion rate to normoglycemia among some dosing groups, effectively normalizing glucose homeostasis in this at-risk population. This result highlights the potential utility of the drug duo not only in weight management but also in the prevention of type 2 diabetes progression.

Safety and tolerability profiles were largely consistent with prior experience of the individual agents. Adverse events reported in the bimagrumab arms, such as mild-to-moderate acne and muscle spasms, warrant further investigation to optimize dosing and minimize side effects. The study’s double-blind, placebo-controlled design lends strong credibility to these conclusions while advocating continued clinical exploration to refine this promising therapeutic strategy.

Importantly, these results advocate for a paradigm shift in obesity treatment evaluation, moving beyond conventional weight and body mass index (BMI) metrics toward more precise assessments of body composition. Emphasizing lean body mass preservation in clinical outcomes acknowledges the multidimensional complexity of obesity and the metabolic consequences of tissue-specific weight changes.

Funded by Eli Lilly and Company and orchestrated under the auspices of Versanis Bio—a Lilly subsidiary—this trial signifies a collaboration between industry and academic research, fostering innovation in metabolic medicine. The Pennington Biomedical Research Center continues to spearhead multidisciplinary investigations into metabolic disorders, leveraging extensive clinical infrastructure and expertise.

As obesity prevalence escalates globally and current therapeutic options grapple with limitations, the synergistic administration of semaglutide and bimagrumab offers renewed hope for patients and clinicians alike. This approach, combining an appetite-suppressing incretin analog with a muscle-preserving activin antagonist, may redefine standards of care, emphasizing both fat mass reduction and muscle conservation.

Future research trajectories will focus on long-term durability of these effects, mechanistic insights into tissue-specific pathways modulated by the drug combination, and broader evaluations in diverse patient populations. As personalized medicine evolves, therapies targeting multiple biological axes might emerge as indispensable tools in tackling obesity’s multifaceted challenges.

The clinical implications of this study extend beyond weight metrics, encompassing cardiovascular risk mitigation, inflammation reduction, and diabetes prevention. It heralds a new era where preserving metabolic health and functionality through tailored pharmacological combinations becomes paramount in obesity management.

In conclusion, the BELIEVE phase 2 trial’s compelling demonstration that semaglutide and bimagrumab, alone but particularly in concert, yield significant and sustained weight loss with preservation of lean mass marks a critical milestone. This dual-action therapy holds transformative promise and is poised to influence future discourses and treatments in metabolic health sciences.

Subject of Research: People

Article Title: Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

News Publication Date: March 5, 2026

Web References:
– https://www.nature.com/articles/s41591-026-04204-0
– http://www.pbrc.edu

References:
Heymsfield, S.B., et al. “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial.” Nature Medicine, 2 March 2026, DOI: 10.1038/s41591-026-04204-0.

Keywords: Obesity, GLP-1 receptor agonist, semaglutide, bimagrumab, activin signaling blockade, lean mass preservation, randomized controlled trial, metabolic health, weight loss, inflammation, adiponectin, prediabetes

The utilization of GLP-1 receptor agonists, such as semaglutide and liraglutide, has revolutionized the management of type 2 diabetes and provided robust strategies for weight loss. Recently, the approval of tirzepatide, which uniquely combines actions of GLP-1 and GIP, has expanded therapeutic options for both obesity and diabetes management. The clinical community is increasingly focused on understanding not just the efficacy of these drugs in facilitating weight loss, but also their capacity to mitigate losses in lean muscle mass, an important factor for metabolic health and physical functionality. This study offers vital insights into these concerns, thereby enriching the discussion around obesity treatment strategies.

The six-month prospective cohort study enrolled 200 adults aged between 18 to 65 years with a body mass index (BMI) of 25 kg/m² or higher, indicative of overweight or obesity. Participants were divided into two groups, with 120 individuals receiving tirzepatide and 80 individuals receiving semaglutide. In addition to pharmacological intervention, subjects received education on resistance training and dietary protein intake, emphasizing a multifaceted approach to weight management. Standardized education provided by a board-certified obesity physician helped ensure participants were well-equipped to utilize the medications effectively.

To accurately assess body composition changes over the six-month intervention, researchers employed bioelectrical impedance analysis using the InBody 570 system. This advanced body composition analyzer provided comprehensive data on muscle, fat, and water distribution in the participants, allowing for a detailed understanding of shifts in body composition attributable to the management strategies deployed. By measuring parameters such as skeletal muscle mass and body fat percentage, the researchers could glean insights on how these therapies influenced both fat loss and muscle retention.

As the results unfolded, data showed promising outcomes in body weight and composition changes post-intervention. At the conclusion of the six-month period, female participants exhibited an average weight reduction from 156 pounds (71 kg) to 137 pounds (62 kg), translating to a significant 12% loss. Male participants experienced a similar trend, with average weights decreasing from 223 pounds (101 kg) to 193 pounds (88 kg), marking a noteworthy 13% reduction. Such findings suggest that both medications are effective tools in the battle against obesity, delivering substantial weight loss results among participants.

Diving deeper into the body composition metrics, the research revealed that women lost an average of 10.8 kg of fat mass, while concurrently experiencing only a minimal decline in muscle mass of 1.4 pounds (0.63 kg). In contrast, male participants shed an even more significant amount of fat mass at 25 pounds (12 kg) but experienced a greater relative decline in muscle mass of 2.4 pounds (1 kg). These results suggest that both genders benefited from the weight loss therapies provided; however, it also highlighted the importance of vigilant oversight in maintaining muscle mass during such weight loss initiatives.

Monitoring adherence to the medication regime was a critical aspect of the study, revealing impressive statistics: 95% of participants reported adherence at the three-month mark and 89% maintained compliance by the six-month check-in. These figures underscore the potential effectiveness of the interventions when patients are genuinely engaged and supported throughout their journey. The qualitative data collected from participants indicated that adherence to resistance training routines and consistent protein intake were positively correlated with muscle preservation, reinforcing established notions about the importance of physical activity and dietary choices in the context of obesity management.

Overall, the six-month study elucidates the effectiveness of GLP-1 and dual GLP-1/GIP receptor agonists in promoting substantial weight loss while mitigating muscle mass decline. While some muscle loss is an inherent part of weight loss, the data suggests patients under the care of specialized obesity physicians can achieve favorable outcomes that prioritize lean mass preservation. Initial findings indicate key factors such as protein intake, medication adherence, and structured follow-up play critical roles in optimizing patient success during these weight loss therapies.

With the study still ongoing, further analysis is anticipated to illuminate finer details regarding the comparative effects of tirzepatide and semaglutide, particularly in regards to their differential impacts on muscle and fat mass retention. It is evident that this evolving area of research will contribute significantly to the clinical guidelines surrounding obesity treatment, reinforcing the necessity for tailored approaches that balance effective weight loss with vital muscle preservation.

As the research unfolds, the authors emphasize a call to action for more robust investigations into dietary patterns and exercise strategies complementing these pharmacologic interventions. The overarching goal is to better delineate the holistic management of obesity that does not merely focus on numerical weight loss but also preserves and enhances the functional health of individuals battling this complex condition. By fostering continued exploration in this critical facet of obesity treatment, healthcare professionals can enhance the quality of life for countless individuals impacted by obesity.

Subject of Research: GLP-1 and dual GLP-1/GIP receptor agonist therapy for weight loss and muscle preservation
Article Title: GLP-1 and Dual Agonist Therapy: Preserving Muscle Mass During Weight Loss
News Publication Date: 9-Apr-2025
Web References: [Specify if available]
References: [Specify if available]
Image Credits: [Specify if available]

Keywords: GLP-1, tirzepatide, semaglutide, obesity, weight loss, muscle preservation, body composition, resistance training, protein intake